Recurrent PNET with MGMT methylation responds to temozolomide

Canadian Journal of Neurological Sciences

Volumn 36, Issue 5, 2009, Pages 654-657

  Oh, Jiwon ^a,d   Bilbao, Juan M ^b   Tsao, May N ^a   Fazl, Mahmood ^a   Guiot, Marie Christine ^c   Del Maestro, Rolando F ^c   Perry, James R ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DRUG SUBSTITUTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMITIVE NEUROECTODERM TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLATION; NEUROECTODERMAL TUMORS, PRIMITIVE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 69549106003     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100008209     Document Type: Article

References (11)

1. Rao RD, Robins HI, Mehta MP. Late recurrence of a primitive neuro-ectodermal tumor. Oncology. 2001;61:189-191
2. Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T. A supratentorial primitive neuroectodermal tumor in an adult: a case report and review of the literature. J Neurooncol. 2008; 86(2):217-224 (Pubitemid 350263421)
3. Kim DG, Lee DY, Paek SH, Chi JG, Choe G, Jung HW. Supratentorial primitive neuroectodermal tumors in adults. J Neurooncol. 2002;60:43-52. (Pubitemid 35153533)
4. Terheggen F, Troost D, Majoie CB, Leenstra S, Richel DJ. Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide. J Neurooncol. 2007;82:113-116 (Pubitemid 46252283)
5. Brandes AA, Palmisano V, Monfardini S. Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev. 1999;25:3-12. (Pubitemid 29178533)
6. Durando X, Thivat E, Gilliot O, Irthum B, Verrelle P, Vincent C, et al. Temozolomide treatment of an adult with a relapsing medulloblastoma. Cancer Invest. 2007;25:470-475 (Pubitemid 47450682)
7. Poelen J, Bernsen HJ, Prick MJ. Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg. 2007;107:51-54 (Pubitemid 47071626)
8. Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol. 2005;252:291-299 (Pubitemid 40562162)
9. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, et al. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940-942 (Pubitemid 23126688)
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
11. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008;115:261-262